What it likely means is that it is well on its way in preparation. It probably has not been submitted yet to the RAs for approval.
What this likely also means is that top line WILL NOT be announced at ASCO. I doubt very much that any reservation has been made for Industry Theatre, especially in view of this lack of announcement. One has to wonder why all this money, which NWBO can ill afford, is spent on a lavish booth/presence for a "nothing burger." Investor expectations will be dashed if not already done so. Forget about any news at the vaccine congress. That will come and go with nada. Next is ASCO. it's beginning to look a lot like the latter part of 2019. I would not be shocked if top line were announced sometime in 2020. That is "clear vision". By that time, the stock price should be in single digits. Even with grand slam results, the share price may not even spike to a dollar(a 9x multiplier which is rather generous on $0.09/share=$0.81) and may rather quickly settle back on or about current levels. Even with RA approvals, I doubt that the stock will even appreciate to a couple of bucks. The market, in NWBO's case, will want evidence of market penetration, revenues/profits, etc. before any serious appreciation. This is a very long term investment. Time for serious re-evaluation, if Innes really said that to you. JMHO.
AI
Market Data 
Markets 
